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Abstract
Ovarian cancer (OvCa) is the fifth most common cause of death from all cancers among women in United Sates and the
leading cause of death from gynecological malignancies. While most OvCa patients initially respond to surgical debulking
and chemotherapy, 75% of patients later succumb to the disease. Thus, there is an urgent need to test novel therapeutic
agents to counteract the high mortality rate associated with OvCa. In this context, we have developed and engineered
Nanoceria (NCe), nanoparticles of cerium oxide, possessing anti-oxidant properties, to be used as a therapeutic agent in
OvCa. We show for the first time that NCe significantly inhibited production of reactive oxygen species (ROS) in A2780 cells,
attenuated growth factor (SDF1, HB-EGF, VEGF165 and HGF) mediated cell migration and invasion of SKOV3 cells, without
affecting the cell proliferation. NCe treatment also inhibited VEGF165 induced proliferation, capillary tube formation,
activation of VEGFR2 and MMP2 in human umbilical vascular endothelial cells (HUVEC). NCe (0.1 mg/kg body weigh)
treatment of A2780 ovarian cancer cells injected intra-peritoneally in nude mice showed significant reduction (p,0.002) in
tumor growth accompanied by decreased tumor cell proliferation as evident from reduced tumor size and Ki67 staining.
Accumulation of NCe was found in tumors isolated from treated group using transmission electron microscopy (TEM) and
inductively coupled plasma mass spectroscopy (ICP-MS). Reduction of the tumor mass was accompanied by attenuation of
angiogenesis, as observed by reduced CD31 staining and specific apoptosis of vascular endothelial cells. Collectively, these
results indicate that cerium oxide based NCe is a novel nanoparticle that can potentially be used as an anti-angiogenic
therapeutic agent in ovarian cancer.
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Introduction
In the United States, 27,000 women are newly diagnosed and
approximately 14, 000 women die from OvCa annually [1]. Such
high mortality rates are due to majority of patients (75%)
presenting with advanced (stage III or greater) disease at the time
of diagnosis [2]. More than 90% of the patients have better
prognosis if the cancer is detected in its earliest stages. Treatment
of epithelial ovarian cancer generally involves surgical debulking
followed by chemotherapy with a combination of platinum and a
taxane-containing agent. However, majority of patients recur and
ultimately succumb to their cancer. Consequently, there is an
urgent need to develop new therapeutics that can be more effective
in treating ovarian cancer and delaying or preventing recurrences.
Novel therapies that target ovarian tumorigenesis are extensively
been researched, but we have yet to come up with a promising
drug.
Nanotechnology based tools and techniques are rapidly
emerging in the fields of medical imaging and targeted drug
delivery. Cerium oxide is a rare-earth oxide that is found in the
lanthanide series of the periodic table. Nanocrystalline cerium
oxide (nanoceria) exhibits a blue shift in the ultraviolet absorption
spectrum, the shifting and broadening of Raman allowed modes
and lattice expansion as compared to bulk cerium oxide indicating
its unique properties. NCe has emerged as a lucrative material in
biomedical science due to its unique ability to switch oxidation
states between (III) and (IV) depending upon the environment.
The ability to switch between mixed oxidation states of nanoceria
is comparable to biological antioxidants. This imparts nanoceria
with a very important biological property of radical scavenging
which can be tuned based upon the retention of oxygen vacancies
(defects) and concentration of Ce3+ species in nanoceria. The
reversibility of oxidation state is the key property in making
nanoceria a potent antioxidant, thereby reducing the need for
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frequent repeated dosage. Previous studies have demonstrated that
cerium oxide nanoparticles possess excellent antioxidant properties
and act as potent, regenerative free radical scavengers in biological
systems [3,4,5]. These regenerative antioxidant properties are due,
in part, to the valence structure of the cerium atom combined with
inherent defects in the crystal lattice structure, which are
magnified at the nano-scale. It has been suggested that the unique
structure of engineered cerium oxide nanoparticles, with respect to
valence and oxygen defects, promotes cell longevity and decreases
toxic insults by virtue of its antioxidant effects that occur when the
nanoparticles enter the cells [6], preventing the accumulation of
reactive oxygen species (ROS) in the cell [3].
Tumor angiogenesis is characterized by the formation of new
irregular blood vessels from a preexisting vascular network. This
abnormal angiogenesis is required for the growth, survival, and
metastasis of most solid tumors [7,8]. Vascular endothelial growth
factor (VEGF) is one of the most important pro-angiogenic factors,
which acts as a mitogen for vascular endothelial cells in vitro and as
an angiogenic factor in vivo [9]. It is over expressed in various
human cancers [10,11,12,13] including OvCa. Recently, it has
been suggested that ROS plays an important role in regulating
tumor induced angiogenesis by controlling VEGF production.
Enhanced production of VEGF has been shown to correlate with a
poor outcome for patients with both early and advanced OvCa.
Various anti-angiogenic agents have been and are undergoing
evaluations in ovarian cancer clinical trials. A phase II study of
single-agent bevacizumab (a monoclonal antibody directed against
VEGF) showed promising results [14]. Therefore, VEGF signaling
is becoming the focus of anti-angiogenic-targeted therapy in
OvCa.
In the present study, we have tested cerium oxide nanoparticles
as a therapeutic agent both in vitro and in vivo in OvCa cells. Our
data demonstrates that NCe was able to inhibit growth factor
mediated, migration and invasion of SKOV3 cells, VEGF165
induced proliferation, capillary tube formation and activation of
VEGFR2 and MMP2 in HUVEC cells. More importantly NCe
treatment inhibited tumor growth in vivo by inhibiting angiogen-
esis, specifically by targeting vascular endothelial cells.
Materials and Methods
Reagents and Antibodies
Trypan Blue, MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide) and HB-EGF were from Sigma. SDF1,
VEGF165 and HGF were purchased from R&D Systems (MN,
USA). Ki-67 and VEGF antibodies were from Dako (Glostrup,
Denmark) and Abcam (MA, USA) respectively. CD31 (PECAM)
was from Santa Cruz Biotechnology (CA, USA).
Cell Culture
Human ovarian cancer cell line SKOV3 and HUVEC were
from American Type Culture Collection. A2780 and C200 cell
lines were a kind gift of Dr. Tom Hamilton (Fox Chase Cancer
Center). OvCa cell lines were maintained and cultured in
complete RPMI media containing 10% FBS, antibiotics. HUVEC
cells were maintained in EBM-2 media purchased from Lonza
(Denmark).
Nanoparticle Synthesis
Cerium Oxide nanoparticles were prepared by wet chemical
synthesis as previously described [15,16,17]. Briefly, cerium nitrate
hexahydrate was dissolved in deionized water and then filtered
using a 200 nm filter to get rid of any freely suspending
particulates. The solution containing cerium ions was then
oxidized using hydrogen peroxide and ammonium hydroxide.
The pH of the solution was adjusted between 3.5–4.0 by using
nitric acid or ammonium hydroxide. All the glassware were
autoclaved before being used for synthesis. The pH and the zeta
potential of the suspension was closely monitored as the solution
was allowed age at room temperature for next several days until
the formation of nanoparticles with predominantly Ce3+ concen-
tration was observed using UV-Visible spectrophotometry.
Nanoparticles Characterization
Change in the oxidation states of the as-prepared nanoparticles
in solution was monitored using UV-Visible spectrophotometry.
Aliquots from the parent sample were taken for absorbance
measurements by using Perkin Elmer 750 S spectrophotometer.
The particle morphology and size distribution was studied using
high-resolution transmission electron microscopy (HRTEM). The
size of the nanoparticles in as prepared solution prior to use in in-
vitro and in-vivo studies was also monitored using dynamic light
scattering (DLS). The oxidation states of cerium inthe particles
were confirmed using X-ray photoelectron spectroscopy (XPS).
For High Resolution Transmission Electron Microscopy
(HRTEM) a drop of suspension of nanoparticles was casted on
the carbon-coated copper grid. The HRTEM images of the as-
prepared particles were obtained with a Philips (Tecnai Series)
operated at 300 keV. The XPS data were obtained using a 5400
PHI ESCA (XPS) spectrometer. Samples were drop casted on a
silicon wafer and dried inside a nitrogen glove box to avoid the
oxidation of cerium from atmospheric oxygen and transferred
using a sample transfer chamber without exposing the samples to
atmosphere. Only limited scans were obtained to avoid x-ray
damage of cerium. An initial scan was saved separately to compare
with the combined 5 scan results and showed no difference in the
Ce3+/Ce4+ ratio. The base pressure during XPS analysis was 1029
Torr and Mg-Ka X-ray radiation (1253.6 eV) at a power of 200 W
was used as x-ray source. The binding energy of Au (4f7/2) at
84.060.1 eV was used to calibrate the binding energy scale of the
spectrometer. Any charging shift produced in the spectrum was
corrected by referencing to the C (1 s) position at (284.6 eV) [13].
XPS spectra smoothening and baseline subtraction was carried out
using PeakFit (Version 4) software.
Migration and Invasion Assays
SKOV3 cells were grown in serum-free media overnight. Cell
migration and invasion were measured as described [18] with
modifications. Briefly, cell suspensions (500 ml, 2.56104 cells) were
seeded on the top of uncoated (migration assay) and Matrigel-
coated (invasion assay) transwell plates (8-mm pore diameter; BD
Biosciences). Serum-free cell suspensions (500 ml) were added to
the top chamber of the transwell. The lower chambers contained
serum free media containing various growth factors including
SDF1, HB-EGF, VEGF165 and HGF at the concentration of
25 ng/ml. Cells invading the lower chamber were stained with
0.5% crystal violet (60% PBS, 40% EtOH) and counted with an
inverted microscope. The results from at least two independent
experiments in triplicate are presented.
Proliferation Assays
(i) MTT assay: 2.5–5.06104 cells were plated in 24 well plates in
triplicates and treated with indicated concentrations of NCe for
72 h. MTT assay was performed as described before [19], to
ascertain the number of live cells. (ii) Thymidine incorporation:
Proliferation of cells was also determined by [3H]-thymidine
incorporation into DNA as described before [20]. In brief, 2.5–
5.06104 cells were plated in 24 well plates in triplicates and treated
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with indicated concentrations of NCe for 72 h. Each group was
treated with 1 mCi of [3H]thymidine in the same medium for 6 h.
The adherent cells were fixed by 5% trichloroacetic acid and lysed
in SDS/NaOH lysis buffer. Radioactivity was measured by
Beckman LS3801 liquid scintillation counter (Canada).
Colony Formation Assay
2000 cells were plated in triplicates in 6-well plates and treated
with indicated concentrations of NCe. The cells were allowed to
form colonies for up to 2–4 weeks (depending on the cell line) and
Figure 1. Preparation and characterization of NCe. High resolution transmission electron micrographs show the presence of A loose
agglomerates of 15–20 nm at low magnification B individual 3–5 nm crystallites. The d spacing of 0.31 nm shows the presence of planes of ceria
while the selected area electron diffraction (SAED) pattern confirms the presence of fluorite lattice of cerium oxide. The trend in oxidation state of
nanoceria in C shows that the synthesized nanoparticles have predominance of trivalent oxidation state that undergoes a slow transformation to
Ce+3 oxidation state over a period of 28 days D x-ray photoelectron spectrum from a reference ceria sample in which cerium is predominantly in +4
oxidation state is compared to the spectrum from a 4 weeks aged sample of nanoceria demonstrating the high concentration of Ce in +3 oxidation
states. E. Basal levels of ROS in ovarian cancer cell line. A2780 cells were treated with NCe (50–100 mM) for 48 h. Cells were washed with PBS and
loaded with DCF-DA dye (5 mM) and fluorescence was recorded at excitation 485 nm and emission 530 nm for various time periods (5–60 min). Wells
containing only cells without DCFDA dye (cross) or without cells containing DCFDA dye (filled diamond) were used as a blank. F. Bar graph represents
ROS levels at the 60 min of treatment with DCF-DA dye. Results are shown as mean 6 S.D. of 4 samples. ***p,0.001 NCe at 100 uM; *p,0.05 NCe
compared to untreated cells using two-tailed Student’s t-test (Prism).
doi:10.1371/journal.pone.0054578.g001
Figure 2. NCe treatment did not affect proliferation and colony formation in ovarian cancer cell lines. A. Percent viability of A2780,
C200 and SKOV3 cells treated with indicated doses of NCe (25–200 mM) as determined by MTT assay. The data is represents three individual
experiments done in triplicates. NS: not significant, compared to untreated cells at respective time point using two-tailed Student’s t-test (Prism). B.
For colony formation, 2000 cells/well (A2780, C200 and SKOV3) were plated in 6-well plates and treated with indicated concentrations of NCe, every
third day for 2 weeks until colonies were formed. The colonies were stained with MTT and counted. The data represents three separate experiments
done in triplicates. NS: not significant compared to untreated cells using two-tailed Student’s t-test (Prism).
doi:10.1371/journal.pone.0054578.g002
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media was replaced every fourth day. Colonies were stained with
MTT and counted as described before [19].
Measurement of ROS
ROS was determined using the membrane-permeable fluores-
cent dye 6-carboxy 29, 79-dichlorodihydrofluorescein diacetate
(DCFDA) in serum-free medium as described previously [21,22].
The cultured cells, with or without treatment with NCe, were
treated with 5 mM DCF dye in PBS and change in fluorescence
was recorded at excitation 485 nm and emission 530 nm for
various time period from 10 to 60 min using a Soft Max Pro
spectrofluorometer (Molecular Devices, Sunnyvale, CA).
Immunoblot Analysis
After stipulated time of incubation in the presence or absence of
indicated amounts of NCe, immunoblot analysis with specific
antibodies was performed as previously described [19,20,21,22].
In brief, treated and untreated HUVEC cells with VEGF165
(25 ng/ml) and/or NCe at various time period (5–30 min) were
lysed in lysis buffer (50 mM Tris-HCl (pH 7.5), 250 mM NaCl,
5 mM EDTA, 50 mM NaF, and 0.5% Nonidet P-40] containing a
protease inhibitor cocktail (Sigma). 40 mg of proteins were resolved
by SDS-PAGE and transferred onto nitrocellulose membrane.
The membrane was then blocked for 1 h in 5% nonfat dry milk
TTBS (20 mM Tris, 500 mM NaCl, and 0.1% Tween 20, pH 7.5)
and incubated overnight in primary antisera (pVEGFR (Y1175),
pVEGFR (Y951), VEGFR2 or b actin) containing 5% nonfat dry
milk or 5% BSA in case of phospho-antibodies. After incubation
with HRP-conjugated secondary Ab, blots were developed with an
ECL detection system (GE Healthcare, Piscataway, NJ).
In Vitro Vascular Tube Formation Assay
In vitro tube formation assays were performed as described by
Melinda et. al. [23]. In brief, matrigel matrix was uniformly plated
onto 8-well chamber slides (0.15 ml) and incubated at 37 C for
30 min. 26105/ml HUVEC cells were treated with NCe (25–
50 mM) and mixed with cells in the presence or absence of
VEGF165 (25 ng/ml) and transferred to each well (200 ml) coated
with matrigel. The plates or slides were incubated at 37uC for 16 h
and imaged under a phase contrast inverted microscope at 10X
objective magnification.
Zymography Assay
For MMP2 activity, HUVEC cells were treated with VEGF165
(25 ng/ml) in the presence or absence of NCe (25–50 mM). Post
18 h, cell supernatant was collected, centrifuged at 12,000 g and
25 ml of volume was mixed with 56 SDS loading buffer without
reducing agent and ran on 10% tris-glycine gel containing gelatin.
Gel was washed twice for 1 h with renaturating solution (2.5%
tritonX100 in 50 mM Tris pH 7.4, 5 mM CaCl, 1 mM ZnCl2) to
remove SDS and renature MMPs. After rinsing gel with deionized
water, gel was incubated overnight at 37uC with buffer containing
50 mM Tris pH 7.4, 5 mM CaCl, 1 mM ZnCl2. Next day, gel
was stained with 0.5% Coomassie G250 followed by de-staining to
see MMP2 activity in gel.
Animals
Ethics statement. 6–8 wk old female nude mice were
purchased from the National Cancer Institute-Frederick Cancer
Research and Development Center (Frederick, MD). All mice
were housed and maintained under specific conditions in facilities
at Mayo Clinic Rochester, MN. The facilities are approved and
inspected by the American Association for Accreditation of
Laboratory Animal Care (AAALAC Accreditation # 000717)
and in accordance with current regulations and standards of the
U.S. Department of Agriculture, U.S. Department of Health and
Human Services, and NIH. All studies were approved and
supervised by the Mayo Clinic Institutional Animal Care and Use
Committee (IACUC) under the protocol number A11309. After
tumor induction, mice were monitored daily for signs of any
distress. Regular health checks are also performed by the Mayo
veterinarian staff. Mice were humanly sacrificed when the tumor
burden reached the mandate weight in untreated mice.
Mice were maintained according to Institutional IACUC-
approved protocol. 26106/200 ml cells suspended in PBS were
injected into the intra-peritoneal cavity (day 0) of 6–7 week old
nude mice as described before [24]. Mice were randomized into
two groups. NCe treatment at the dose of 0.1 mg/kg body weight
began 3 days post inoculation of cells and was given intra-
peritoneally at every 3rd day till end of the study. The control
group received PBS injections. Mice were sacrificed at 4 weeks and
tumors were fixed in formalin for sectioning. Blood was collected
in heparin coated tubes to obtain plasma. Liver, kidney, heart and
spleen from all animals were formalin fixed and processed. One
tumor and organ slide from each mouse was stained with H&E.
Cytotoxicity assays. Blood was collected in heparin coated
tubes just before mice were sacrificed. Plasma isolated from blood
of six mice from each group was subjected to analysis of a panel of
Figure 3. NCe treatment attenuated cell migration and
invasion in ovarian cancer cell. A. Effect of NCe on various growth
factors mediated cell migration was examined using wound closure
assay as described in Material and Methods. Results are shown as mean
6 S.D. of n = 7. B. To examine effect of NCe on invasion, 16105 SKOV3
cells were seeded into the upper wells with 100 mM NCe in the FIA
chamber in 500 ml culture medium. Various growth factors (EGF,
VEGF165 and SDF1) (25 ng/ml) was added to the underlying media.
24 hrs later, invasion was determined following manufacturer’s
instructions. Results are shown as mean 6 S.D. of triplicates.
***p,0.001 growth factor treated compared to control.
$$$p,0.001 NCe treated compared to growth factor using two-tailed
Student’s t-test (Prism).
doi:10.1371/journal.pone.0054578.g003
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liver function tests (aspartate aminotransferase; alanine amino-
transferase; albumin) and kidney function tests (creatinine; urea;
albumin) as described before [24]. All assays were performed using
kits from Bioassay Systems following the manufacturer’s instruc-
tion (CA, USA).
Determination of NCe in tissues. At the end of the study,
various tissues including tumor, liver, spleen and kidney from NCe
treated group were placed in 70% nitric acid overnight to start the
digestion process. Samples were then microwave digested. The
temperature was ramped to 200uC over 20 min and held there for
another 20 min. Samples were then boiled down to less than 1 ml
each and reconstituted in water to an exact volume of 10 ml.
Cerium levels were assessed using inductively coupled plasma mass
spectroscopy (ICP-MS) as described before [25].
For transmission electron microscopy (TEM), ovarian tumor
isolated from NCe treated mice were fixed in Trump’s fixative (1%
glutaraldehyde and 4% formaldehyde in 0.1 M phosphate buffer,
pH 7.2). Tumor was embedded in Spurr’s resin and thin (90 nm)
sections were cut on a Reichert Ultracut E ultramicrotome, placed
on 200 mesh copper grids and stained with lead citrate.
Micrographs were taken on a TECNAI 12 operating at 120KV.
IHC. Fixed tumors excised from mice were processed for
immunohistochemistry for CD31, Ki-67 and TUNEL (Millipore)
as previously described [24]. H&E staining was performed by
Mayo immunohistochemical Core facilities. Ki-67 and H&E
sections were examined under light microscope and representative
pictograms were taken from 5 different slides of each group. For
CD31 staining, TRITC-labeled secondary antibody was used and
visualized using fluorescent microscope. For double staining, the
slides were first processed for CD31 staining followed by
immunofluorescence TUNEL staining, according to manufactur-
er’s instructions.
Live tumor measurements. Maximum diameter of viable
tumor was calculated by RPG by summing the largest uni-
Figure 4. NCe treatment inhibited ovarian tumor growth in vivo. A. Gross morphology of representative mouse with tumors at day 30 (n = 6).
B. Cumulative abdominal circumference at the end of the study. C. Excised tumor weight from vehicle (PBS) treated and NCe (0.1 mg/kg bd wt; every
third day). Results are shown as mean 6 S.D. of six individual animals. **p,0.01 NCe treated compared to untreated group using two-tailed
Student’s t-test (Prism). D. (i) Representative H&E (x20) photomicrographs exhibiting live (purple) and necrotic (pink, encircled) areas in untreated
and treated xenografts. (ii) Graphical representation of viable tumor size measured as described in Material and Methods. E. (i) Representative Ki-67
staining (x200) of excised A2780 xenografts at day 30. (ii) Count of positive Ki-67 cells from 5 high powered fields (x400) in 3 different xenografts from
each group. Counts are expressed as percentage of control. ***p,0.001 and **p,0.01 NCe treated compared to untreated using two-tailed
Student’s t-test (Prism).
doi:10.1371/journal.pone.0054578.g004
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dimensional diameter of each fragment of tumor using the
Olympus BX-41 microscope and a micrometer. Similarly, necrotic
areas were measured and the composite live tumor size was
calculated from each slide.
Endothelial tube formation. To examine the effect of NCe
on tube formation in HUVEC cells, matrigel matrix was uniformly
plated onto 8-well chamber slides (0.15 ml) and incubated at 37uC
for 30 min. HUVEC cells were counted and diluted to 26105/ml
in medium. Cells were treated with NCe (25–50 mM) was mixed
with cells in the presence or absence of VEGF165 (25 ng/ml) and
transferred to each well (200 ml) coated with matrigel. The plates
or slides were incubated at 37uC for 16 h and imaged under a
phase contrast inverted microscope at 106 objective magnifica-
tion.
Statistical analysis. The data were statistically analyzed
using two-tailed Student’s t-test (Prism). ***P,0.001;
**P,0.01,*P,0.05; NS: not significant compared to untreated.
Results
Synthesis and Characterization of Cerium Oxide
Nanoparticles
Cerium oxide nanoparticles used in this study contains
individual crystallites of 3–5 nm that are loosely agglomerated to
15–25 nm. As the synthesis process is free from any organic
surfactant, the hard agglomeration of nanoparticles is controlled
by tightly controlling the pH of the nanoparticles below 3.5 during
synthesis to keep them in colloidal range. Nanoparticles can be
diluted in aqueous or cellular media after the synthesis. Figure 1 A
and B shows the high resolution transmission electron micrographs
(HRTEM) of NCe nanoparticles. It is evident from the image that
nanoparticles are loosely agglomerated to about 15–25 nm
aggregates which could also be induced by the drying process.
The hydrodynamic radius (37.8 nm 60.8) from the multimodal
size distribution (volume %) analysis of DLS measurements agrees
with the loose agglomerate size of the HRTEM analysis. High
magnification image confirms the lattice planes of NCe in
individual 3–5 nm crystallites. UV-Visible spectroscopy was used
to analyze the oxidation states of cerium oxide nanoparticles
before and after aging treatment. Figure 1 shows the UV-Visible
spectra from fresh and aged cerium oxide nanoparticles clearly
indicating the predominance of Ce+3 oxidation state from the
absorption peak at 252 nm as compared to absorption peak at
298 nm for Ce4+. Further confirmation on the oxidation states of
nanoparticles was obtained from XPS analysis. The XPS spectrum
of cerium is very complex that contains multiple peaks from the
spin orbit coupling of 3d orbitals [26]. Several peaks in the Ce3d
region that have been ascribed to 3d3/2 (899.5, 900.9, 903.5, 906.4
and 916.6) and 3d5/2 (880.2, 882.1, 8885, 888.1 and 898) arising
from multiple valence states of cerium. The spectrum from NCe
shows a predominance of cerium in +3 oxidation state as depicted
by the characteristic peaks at 880.2, 885.0, 899.5 and 903.5 eV.
Taken together the data from characterization of NCe is consistent
with previous reports wherein cerium can be retained in trivalent
oxidation by decreasing the size of the nanoparticles [15,16,17,26].
NCe Treatment Inhibits Production of ROS Levels in
A2780 Cell Line
Cerium oxide nanoparticles have been shown to act as free
radical scavengers by inhibiting the production of reactive oxygen
Figure 5. Bio-distribution of NCe in ovarian tumor bearing nude mice. A. At the end of the study, various organs including tumor, liver,
kidney and spleen were isolated from five individual mice and tissues were digested using microwave as described in method. Level of NCe was
measured using ICP-MS. Data represents mean+SEM of 5 tissues of individual mouse. B. Agglomeration of NCe localized in vacuole in ovarian cancer
tumor examined by TEM as described in Method in detail.
doi:10.1371/journal.pone.0054578.g005
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species (ROS) [3,4,5]. Since, it is well established that ROS
accumulation plays an important role in the initiation and
progression of tumorigenesis in human ovarian cancer
[27,28,29], we examined the effect of NCe on ROS generation
in ovarian cancer cell line A2780. A2780 cell line was treated with
NCe (50–100 mM) and post 48 h of treatment, ROS generation
was measured using DCFH2-DA dye followed by fluorescence
reading. As shown in figure 1E–F, NCe treatment significantly
inhibited ROS levels in A2780 cell line, suggesting that NCe
treatment inhibits basal levels of oxidative stress in A2780 OvCa
cell line.
NCe did not Effect Cell Proliferation in Ovarian Cancer
Cell Lines
To determine if NCe treatment inhibited cell proliferation,
A2780, C200 and SKOV3 were plated in 96 well plates at 46103
cells/well and treated with various concentrations of NCe (25–
200 mM). Cell viability was determined at 72 hrs by MTT assay.
As shown in figure 2A, NCe treatment had no significant effect on
the proliferation or survival of ovarian cancer cell lines. Consistent
with this observation, our clonogenic assays also showed no
change in proliferation rate with increasing NCe concentration
(Fig. 2B). [3H] thymidine uptake in A2780, C200 and SKOV3
cells (Fig. S1), also confirmed that NCe treatment did not alter the
rate of proliferation. Similar results were obtained in additional
ovarian cancer cell lines including CaOV3 and TOV21G (data
not shown). Collectively, these results indicate that NCe treatment
did not significantly inhibit the growth of ovarian cancer cells lines
in vitro.
NCe Inhibited Growth Factor-mediated Cell Migration
and Invasion in vitro
Since, NCe treatment did not affect cell proliferation, we
evaluated the effect of NCe on growth factor mediated cell
migration and invasion. SKOV3 cells grown overnight in low
serum (0.2%) containing medium were scratched using a sterile
200 ml pipette tip, once they reached 90% confluence. Various
growth factors including SDF1, HB-EGF, VEGF165 and HGF
(25 ng/ml) were added individually to the medium in the presence
or absence of NCe (100 mM). 24 hrs later, the rate of wound
closure was calculated. As shown in figure 3A, NCe inhibited all
growth factor mediated cell migration in SKOV3 cell line. Similar
results were obtained for A2780 and C200 cell lines (data not
shown). Next we assessed the effect of NCe in inhibiting GF-
mediated invasion of SKOV3 cells using Boyden chamber
migration assay (BD Bioscience) as previously described [18].
Figure 3B clearly demonstrates that 100 mM NCe treatment
significantly inhibited all growth factor induced invasion of
SKOV3 cells compared to untreated cells. These results indicate
that, NCe has the ability to inhibit migration and invasion of
ovarian cancer cells without affecting cell proliferation.
NCe Treatment Attenuated Tumor Growth in Human
A2780 Ovarian Carcinoma Cell Line Bearing Nude Mouse
Model
To determine the effect of NCe in vivo, nude mice were intra-
peritoneally injected with A2780 cells. Mice were treated with
NCe (0.1 mg/kg body weight) given intra-peritoneally, every third
day till end of the study (day 30) as described in the material and
methods. Figure 4A (top panel) shows a representative photograph
of a NCe treated and untreated mouse bearing A2780 xenograft at
the end of study (day 30). The abdominal circumference,
indicative of the tumor burden in the peritoneum (Fig. 4B) and
the tumor weight (Fig. 4C) in the NCe treated mice were
significantly (p,0.002) reduced compared to untreated mice. The
mean weight of the excised tumors was approximately 33% less in
NCe (4.56+0.345 gm) treated mice compared to vehicle (PBS)
mice (6.79+0.53 gm) (Fig. 4C). This data clearly indicates that
NCe has the ability to restrict ovarian tumor growth in vivo when
administered even at a very low dose (0.1 mg/kg).
Representative H&E staining of A2780 xenografts (Fig. S2 -
206) showed more live cells in untreated xenografts. However,
NCe treated xenografts had significantly more necrotic areas (dead
cells) (Fig. 4Di; 206; non-viable area encircled). To quantitate the
live and dead areas in the xenograft sections, uni-dimensional
measurements of the viable tumor and total tumor size were taken
as described in the methods section. NCe treated tumors had less
viable tumor areas than untreated mice (Fig. 4Dii). To determine
whether the decrease in tumor weight and size following NCe
treatment was due to decreased cell proliferation, immuno-
histochemical analysis of Ki67 was performed. Significant
difference was observed in the number of cells staining positive
for Ki-67 (Fig. 4Ei). Enumeration of Ki-67 positive cells counted
over 5 high power fields of five sections from each group also
showed significant less Ki-67 positive cells in NCe treated
xenografts compared to untreated group (expressed in %age;
Fig. 4Eii), indicating that less number of cells were proliferating
under NCe treatment. Together, these data indicate that NCe has
the ability to restrict ovarian tumor growth in vivo due to decreased
proliferation of OvCa cells.
To examine if NCe is accumulated in tumors, at the end of the
study, tumors were isolated along with major organs including
liver, kidney and spleen from NCe treated groups. NCe was
Figure 6. NCe treatment is non-toxic in nude mice. After
sacrificing animal groups (n = 6) at the end of the study (day 30), blood
was collected in heparin coated tubes and plasma was prepared. A
panel of liver and kidney cytotoxic tests were performed in plasma
prepared from control and NCe treated mice as per the manufacturer’s
instructions, A. ALT (Alanine Transaminase), B. AST (Aspartate
Transaminase), C. Albumin, D. BUN (Blood Urea Nitrogen), E. Creatinine
and F. Glucose.
doi:10.1371/journal.pone.0054578.g006
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isolated and detected using ICP-MS as described in the methods.
As shown in figure 5A, high levels of NCe could be detected in
tumors followed by spleen and liver levels. Least amount of NCe
was detected in kidney. To further strengthen this observation, we
performed electron microscopy in tumors isolated from NCe
treated mice and found the agglomeration of NCe in tumor tissue,
further suggesting that NCe is accumulated in tumor and may be
one of the reasons for decreased tumor burden in treated mice
compared to vehicle treated group.
To determine the cellular toxicity of NCe in vivo, the vital organs
(liver heart, spleen, kidney and lungs) were excised from untreated
and NCe treated mice at the end of the study and formalin fixed.
H&E staining of the various sections revealed that the morphology
of all organs from treated and untreated mice appeared to be
normal and no necrosis was observed (Fig. S3A-E; 1006). Analysis
of liver function (aspartate aminotransferase, AST; alanine
aminotransferase, ALT; albumin) and kidney function (creatinine;
blood urea nitrogen, BUN; albumin) in plasma collected, showed
no significant difference in the untreated and NCe treated mice.
All values were found within the normal limits in both groups
(Fig. 6A–E). No fluctuation in the glucose levels was observed
either (Fig. 6F). These data show that NCe treatment on every
third day for 4 weeks at the dose of 0.1 mg/kg is safe and does not
result in tissue cytotoxicity or any abnormal physiological vital
functions.
NCe Inhibited Metastasis in Human A2780 Ovarian
Carcinoma Cell Line Bearing Nude Mouse Model
Since our in vitro data showed that NCe treatment inhibited
growth factor induced migration and invasion, we further
examined for the presence of metastasis in various organs. H&E
staining of sections from various organs revealed no invasion of
tumor cells inside liver, spleen and kidney (data not shown),
although tumor nodules were visible on their surface in untreated
mice. However, large metastatic nodules were observed in lungs of
untreated mice, which were significantly reduced in lungs of NCe
treated mice. Figure 7A (4006). More importantly, the number of
nodules were also significantly decreased upon NCe treatment
(Fig. 7B). These results are consistent with our in vitro data where,
NCe treatment inhibited migration and invasion of tumors cells
in vitro.
NCe Inhibited Angiogenesis in A2780 Ovarian Carcinoma
Mouse Model
As we did not observe any significant effect on cell proliferation
or cell death in ovarian cancer cell lines in vitro but found
significant reduction in tumor growth in vivo, we hypothesized that
this could be a result of inhibition of angiogenesis as it is one of the
important factors implicated in progression of OvCa [30,31]. Also
for a tumor to sustain, grow, proliferate and invade, formation of
Figure 7. NCe inhibits metastasis and vessel formation in A2780 xenografts. A. Representative H&E (x100) photomicrograph depicting
lung metastatic nodules from Untreated and NCe treated mice (arrows point to metastatic nodules). B. Enumeration of metastatic nodules found per
lung from Untreated and NCe treated mice. Total of 5 lung sections were observed to get the average count. *p,0.005 NCe compared to untreated
using two-tailed Student’s t-test (Prism). C. Representative photomicrograph of CD31 staining of blood microvessels (x200) in A2780 xenografts at
day 30. D. Count of average microvessels per high power field (x400) from five fields of three xenograft section from untreated and NCe treated mice.
***p,0.001, NCe treated to untreated using two-tailed Student’s t-test (Prism).
doi:10.1371/journal.pone.0054578.g007
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new vasculature is a prerequisite. Micro-vessel density of tumors
increases in response to various angiogenic factors and low oxygen
availability in the growing tumors, which enables them to avoid
death and proceed towards invasion and metastasis. We evaluated
the micro-vessel density by staining for CD31. CD31 staining of
xenograft sections from NCe treated A2780 tumors showed
significantly less number of CD31 positive micro-vessels (Fig. 7C,
2006) compared to untreated mice. Quantification of positively
stained vessels at high power from 5 different fields of five sections
from each group is shown in figure 7D, 4006. These indicate that
NCe maybe targeting angiogenesis and as a consequence limiting
tumor growth.
NCe Treatment Targets Angiogenesis by Inhibiting VEGF
Signaling in Endothelial Cells
VEGF165, one of the most potent angiogenic factor is
overexpressed in ovarian tumors [32,33,34]. To determine if
NCe treatment could be attenuating angiogenesis by inhibiting
Figure 8. NCe treatment inhibits VEGF165 induced downstream signaling in endothelial cells. A. NCe inhibited VEGF165 mediated
proliferation of HUVEC cells as assessed by measurement of DNA synthesis by [3H]-thymidine incorporation (n = 4). ***, p,0,001; NS not significant
compare with untreated cells. $, p,0.05; $$$, p,0,001 compared with VEGF165 treated cells using two-tailed Student’s t-test (Prism). B. The effect of
NCe on tube formation in HUVEC cells was examined as described in Method and Materials. C NCe treatment inhibited VEGF165 induced
phosphorylation of VEGFR2 (Y1175 and Y951), as seen by immunoblot. D. NCe inhibited VEGF165 induced MMP2 activity in HUVEC without affecting
MMP9 activity examined by zymography.
doi:10.1371/journal.pone.0054578.g008
Figure 9. NCe treatment potentiates the endothelial apoptosis of ovarian tumor in vivo. Double of staining CD31 and TUNEL was
performed as described in Methods. First panel depicts CD31-FITC labeled endothelial cells as part of a microvessel (red, x400). Second panel depicts
the same microvessel stained positive for apoptotic marker TUNEL labeled with FITC (green, x400). Third panel shows blue nuclei stained with DAPI
(x400), indicating presence of tumor cells. The last panel shows merged image of all first three panels. The microvessel appears yellowish due to co-
localization of CD31 and TUNEL in NCe treated tumor section.
doi:10.1371/journal.pone.0054578.g009
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VEGF production/levels, we initially examined the effect of NCe
on VEGF165 production in SKOV3 cells in vitro. SKOV3 cells
were grown, kept in serum free conditions overnight and treated
with EGF to stimulate VEGF production. Post 24 h, conditioned
media was used to estimate the levels of VEGF by ELISA. As
shown in Fig. S4A, treatment with EGF induced the production of
VEGF in SKOV3 cells, while no changes were found in VEGF
levels when cells were treated with NCe. Under similar
experimental conditions we also estimated the levels of IL-8,
which is involved in OvCa pathogenesis and VEGF production
[35]. Similar to VEGF, NCe did not alter the levels of IL-8
production (Fig. S4B). Consistent with this observation, immuno-
staining for VEGF165 levels in the A2780 xenografts from NCe
treated and untreated mice also showed no change in the VEGF
expression (Fig. S4C). Collectively, these findings clearly suggest
that NCe does not modulate VEGF and IL-8 levels in ovarian
cancer cells but restricts angiogenesis by some other mechanism.
Since NCe treatment significantly reduced the number of
microvessels in treated xenografts without affecting the VEGF
expression, we surmised that NCe may modulate angiogenic
signaling downstream of VEGF165 in endothelial cells. NC e
treatment attenuated VEGF165 mediated proliferation of HUVEC
cells as determined by thymidine incorporation assay (Fig. 8A).
The next step for proliferating endothelial cells is to form new
vessels. HUVEC cells (26104) were plated on matrigel coated 96
well plate in the presence of NCe (25–50 mM) with or without
VEGF165 (25 ng/ml) as an angiogenic stimuli. VEGF165 induced
endothelial tube formation was significantly attenuated by NCe
treatment (Fig. 8B). NCe treatment also reduced the phosphor-
ylation of VEGFR2 at Tyr1175 and Y951in HUVEC cells in
response to VEGF165 treatment (Fig. 8C). Additionally, NCe
treatment also inhibited VEGF induced MMP2 activity in
endothelial cells as determined by zymography assay (Fig. 8D).
These data clearly suggest that NCe treatment inhibits VEGF
mediated downstream signaling in endothelial cells and as a result
may interfere with proliferation and survival of endothelial cells.
NCe Treatment Specifically Targets Endothelial Cells
in vivo
To determine if NCe has any inhibitory effect on vessel
formation in vivo as observed in vitro, we performed double staining
with CD31 and TUNEL in the tumor xenograft slides from both
treated and untreated mouse groups. As shown in Fig. 9, CD31
antibody recognized endothelial cells in the microvessels (stained
red, first panel). Cells undergoing apoptosis were detected by
performing TUNEL staining (stained green, second panel). Upon
superimposing, it was observed that TUNEL and CD31 stains
were co-localized (yellow, last panel), indicating that it was the
endothelial cells specifically in the microvessels that were
undergoing apoptosis under NCe treatment. These data suggest
a potential role for NCe as an anti-angiogenic molecule by
targeting endothelial cells and VEGF signaling.
Discussion
The science of developing nanoparticles into nano-medicine to
encounter human diseases for better health outcomes is a rapidly
progressing field. A number of metal nanoparticles have been
designed and shown to be of therapeutic interest in various animal
models, especially in the field of cancer [36,37]. Successful
incorporation of nanoparticles as anti-cancer therapeutics can
open an entirely new avenue for cancers like ovarian, where
chemotherapeutic options are limited and high mortality is a
serious concern. In this regard, we investigated the potential of a
specially designed cerium oxide nanoparticles, (nanoceria; NCe) as
a therapeutic agent in ovarian cancer.
In the present study, we show for the first time that NCe has the
potential to inhibit ovarian tumor growth and metastasis. We show
that NCe attenuated basal levels of oxidative stress, invasion and
migration of ovarian cancer cells without modulating their cell
growth. It also significantly attenuated tumor growth in A2780
bearing nude mice when given intra-peritoneally. Our study found
a novel property of NCe as an anti-angiogenic as its treatment
reduced the microvessel density in ovarian xenografts, inhibited
proliferation and induced apoptosis in endothelial cells in vitro and
in vivo respectively. Additionally, it also attenuated VEGF medi-
ated downstream signaling in HUVEC. In vivo treatment of NCe
resulted in specific apoptosis of endothelial cells in the microvessels
being formed in the tumor tissue. Overall, our study presents a
novel attribute of NCe as an anti-angiogenic agent, which can be
used as a therapeutic in OvCa and other cancers.
The most attractive property of cerium oxide nanoparticles is
their capacity to serve as free radical scavengers to provide
protection against chemical, biological, and radiological insults
that promote the production of free radicals [3,4,5]. NCe offers
many active sites for free radical scavenging due to its large
surface/volume ratio and mixed valence states (+4 and +3) for
unique redox chemistry. Moreover, its unique regenerative
property (Ce3+-Ce4+-Ce3+) [4] makes NCe long-lived and can
thus confer its beneficial effect for extended periods of time
without limiting the number of frequent dosage. Recently, it has
been reported that NCe selectively conferred radioprotection to
the normal breast cells (CRL 8798) against ROS compared to the
breast cancer cells [5]. It also provided radioprotection against
pneumonitis and gastrointestinal epithelium by reducing ROS
[38,39]. Another recent study showed NCe to bestow protection
from monocrotaline-induced hepatoxicity due to oxidative stress
[40]. NCe has been shown to induce oxidative stress in other
cancer cell lines including human bronchoalveolar carcinoma
derived cell line (A549) and squamous SCL-1 tumor cell line [41].
Our finding that NCe acts as an anti-oxidant in ovarian cancer, is
in agreement with these previous reports. These data suggest that
cerium oxide particles may have differential outcomes of its anti-
oxidant properties dependent on the nature of cell type.
In our study, although the anti-oxidant property of NCe was
able to reduce basal levels of oxidative stress but had no effect on
proliferation of OvCa cell lines in vitro. Interestingly, NCe
inhibited growth factor induced migration and invasion of ovarian
cancer cell lines. Similar to our observation, Tarnuzzer et al [5]
also found non-cytotoxic effect of NCe on MCF7 breast cancer
cell line. However, polymer-coated NCe showed cytotoxic effect
on squamous tumor SCL-1 cells [41]. The discrepancy between
ours and other [41] reports may be due to subtle change in the
surface properties of nanoparticles in various cell types.
On observing that NCe treatment inhibited GF induced
migration/invasion in vitro, we examined its ability to modulate
tumor growth in vivo. We found that administration of NCe
(0.1 mg/kgbdwt) every third day significantly retarded A2780
xenograft growth in vivo which was also accompanied by attenu-
ation of metastatic nodule size and number in lung. This is the first
report that demonstrates the in vivo ability of NCe to inhibit
ovarian tumor growth and metastasis. NCe accumulated mainly in
tumor followed by spleen, liver and then kidney when given to
tumor bearing mice. Uptake of NCe in tumor was further
confirmed by TEM where we were able to detect agglomeration of
NCe. Also, used dose of NCe (0.1 mg/kgbdwt) is well tolerated by
mice without any cytotoxic or adverse physiological effects
observed in the vital organs. These findings are in agreement of
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previous report where NCe at a high concentration of 135 mg/kg
body weight did not cause any death or notable side effect in nude
mice with normal pathology of vital organs [38]. However, a
recent report indicates the toxic effect of NCe in rodents [42]. This
can be accounted for as the dose of NCe used in the previous study
is 1000–2500 times higher (100–250 mg/kg body weight) then
what we have used in our study (0.1 mg/kg body weight) [42].
Although in vitro, NCe treatment did not affect ovarian cancer
cell growth in vitro, we observed decreased staining of Ki-67, a
maker of cell proliferation in vivo in the xenografts, suggesting NCe
treatment might have an effect on the tumor micro-environment
rather than having a direct effect on the tumor cells. To determine
the mechanism by which NCe maybe restricting tumor growth, we
examined the microvessel density in treated and untreated tumor
tissue and found a significant reduction in NCe treated tumors as
evident from CD31 staining, a marker for endothelial cells.
Interestingly, NCe did not modulate VEGF production in vitro and
in vivo. These observations led us to hypothesize that NCe maybe
specifically targeting the endothelial cells responsible for formation
of new vessels.
Angiogenesis is important for tumor development and growth
and VEGF has been shown to be a major angiogenesis inducer
primarily through the VEGF type 2 receptor (VEGFR2) [43,44].
The downstream effects of VEGF mediated signaling include
increase in cell proliferation, tube formation and activation of
matrix metalloproteases to promote degradation of extracellular
matrix. We observed that NCe treatment inhibited VEGF induced
proliferation, capillary tube formation and MMP2 activation in
endothelial cells. NCe treatment attenuated VEGF mediated
phosphorylation of VEGFR2 (Y1175 and Y951), a prerequisite for
VEGF to signal to endothelial cells. Phosphorylation of VEGFR2
(Y1175) is critical for endothelial proliferation and the recruitment
of adaptor proteins including p85 of PI3Kinase and PLCc [45].
Phosphorylation of VEGFR2 at Y951 is important for recruitment
of adaptor proteins [46]. Inhibition of VEGF induced downstream
signaling including proliferation, tube formation and MMP2
activation by NCe treatment indicating a novel anti-angiogenic
property of NCe. Targeting of endothelial cells by NCe in vivo was
also supported by the TUNEL assay in NCe treated xenografts
specific to CD31+ve endothelial cells. The role of oxidative stress
in angiogenesis is an emerging area of investigation [47]. The anti-
angiogenic property of NCe might be modulating VEGF mediated
signaling events which are redox sensitive [44]. This is the first
report demonstrating any cerium oxide nanoparticles to exhibit an
anti-angiogenic property with specificity for endothelial cells.
Anti-angiogenic agents have demonstrated activity in terms of
both response and progression free survival (PFS) in phase II and
phase III clinical trials for women with epithelial ovarian cancer,
both in the front-line and relapsed setting [48,49,50,51]. But
recent emerging reports indicate the therapy to be associated with
increased fatal reactions [52,53,54,55]. Therefore, novel strategies
and agents that can target angiogenesis without many side effects
are still required.
Taken together, our results reveal a new role of cerium oxide
nanoparticles as a novel, non-toxic anti-angiogenic agent that
restricted ovarian tumor growth in preclinical mouse model of
ovarian cancer. Our study opens up a new avenue of using
nanoparticles as feasible therapeutics in ovarian cancer. A future
option to increase the efficacy and specificity of NCe, can be
conjugating it with folic acid, a ligand for folate receptor over
expressed in ovarian cancer, as a tool to deliver NCe specifically to
tumor as a novel targeted therapy. Moreover, NCe could be
conjugated with other chemotherapeutic drugs for their specific
delivery as well as enhancement of their cytotoxicity, while
reducing the side effects. The outcome of these studies could open
a new and novel avenue of therapy for ovarian cancer.
Supporting Information
Figure S1 NCe has no effect on cell proliferation of
ovarian cancer cell lines. [3H]Thymidine incorporation
following NCe treatment in A. A2780, B. C200 and C. SKOV3
shows that NCe treatment has no effect on proliferation of ovarian
cancer cells. The data is representation of three separate
experiments done in triplicates. NS, non-significant compared
with control using two-tailed Student’s t-test (Prism).
(TIF)
Figure S2 Representative photomicrograph of H&E
staining (2006) of A2780 xenografts at day 30.
(TIF)
Figure S3 NCe treatment is non-toxic in nude mice
bearing human A2780 carcinoma. After sacrificing animal
groups, different organs of five mice from each group were
formalin fixed, processed for histological sectioning and stained
with H&E to observe morphology of the tissue. Representative
photomicrographs (1006) of A. Liver; B. Heart; C. Spleen; D.
Kidney and E. lungs, show normal morphological architecture in
tissues of both untreated and NCe treated mice.
(TIF)
Figure S4 NCe does not affect the production of VEGF
and IL8 in SKOV3 cells. SKOV3 cells were plated and kept
under serum free conditions overnight before being stimulated by
EGF (10 ng). Post 24 h supernatant was collected to perform
ELISA. A. VEGF levels. B. IL-8 levels. *p,0.01, **p,0.001 of
EGF treated to no treatment. NS = non-significant NCe treated to
untreated; ns = non-significant NCe/EGF treated to EGF treated
using two-tailed Student’s t-test (Prism). C. Representative
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